HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. Co.'s program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. We show 8 historical shares outstanding datapoints in our coverage of HLVX's shares outstanding history.
Understanding the changing numbers of HLVX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like HLVX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching HLVX by allowing them to research HLVX shares outstanding history
as well as any other stock in our coverage universe. |
Free HLVX Email Alerts:
Video: Shares Outstanding Importance
